ProfileGDS5678 / 1415836_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 70% 61% 70% 67% 49% 62% 59% 58% 59% 64% 53% 64% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6203660
GSM967853U87-EV human glioblastoma xenograft - Control 24.4101470
GSM967854U87-EV human glioblastoma xenograft - Control 33.6377961
GSM967855U87-EV human glioblastoma xenograft - Control 44.4875170
GSM967856U87-EV human glioblastoma xenograft - Control 54.0285667
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2642449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.769362
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.528159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5018158
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5256559
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8074364
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2761953
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8525864
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5589359